Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.

Guardado en:

Detalles Bibliográficos
Autores principales:	Ying Li, Yanni Cong, Mingming Jia, Qianqian He, Haiqing Zhong, Yun Zhao, Hang Li, Meining Yan, Jia You, Jia Liu, Lieping Chen, Haiying Hang, Shengdian Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0144328845a498a9c1f543f87d37f7c
record_format	dspace
spelling	oai:doaj.org-article:e0144328845a498a9c1f543f87d37f7c2021-12-02T13:30:20ZTargeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy10.1038/s41467-021-21241-02041-1723https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21241-0https://doaj.org/toc/2041-1723The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.Ying LiYanni CongMingming JiaQianqian HeHaiqing ZhongYun ZhaoHang LiMeining YanJia YouJia LiuLieping ChenHaiying HangShengdian WangNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ying Li Yanni Cong Mingming Jia Qianqian He Haiqing Zhong Yun Zhao Hang Li Meining Yan Jia You Jia Liu Lieping Chen Haiying Hang Shengdian Wang Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
description	The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.
format	article
author	Ying Li Yanni Cong Mingming Jia Qianqian He Haiqing Zhong Yun Zhao Hang Li Meining Yan Jia You Jia Liu Lieping Chen Haiying Hang Shengdian Wang
author_facet	Ying Li Yanni Cong Mingming Jia Qianqian He Haiqing Zhong Yun Zhao Hang Li Meining Yan Jia You Jia Liu Lieping Chen Haiying Hang Shengdian Wang
author_sort	Ying Li
title	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
title_short	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
title_full	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
title_fullStr	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
title_full_unstemmed	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
title_sort	targeting il-21 to tumor-reactive t cells enhances memory t cell responses and anti-pd-1 antibody therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c
work_keys_str_mv	AT yingli targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT yannicong targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT mingmingjia targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT qianqianhe targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT haiqingzhong targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT yunzhao targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT hangli targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT meiningyan targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT jiayou targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT jialiu targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT liepingchen targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT haiyinghang targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy AT shengdianwang targetingil21totumorreactivetcellsenhancesmemorytcellresponsesandantipd1antibodytherapy
_version_	1718392945960288256

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Ejemplares similares